Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth
Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...
Zai Lab (ZLAB) Initiated with a Buy at Scotiabank
Zai Lab (ZLAB – Research Report) received a Buy rating and a $55.00 price target from Scotiabank analyst Louise Chen today. The company’s ...
Zai Lab price target raised to $51 from $44 at JPMorgan
JPMorgan raised the firm’s price target on Zai Lab (ZLAB) to $51 from $44 and keeps an Overweight rating on the shares. The firm updated models ...
Zai Lab announces acceptance of BLA for TIVDAK in cervical cancer
Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, ...
ETF Daily News6d
Zai Lab (NASDAQ:ZLAB) Price Target Raised to $51.00
Shares of ZLAB stock opened at $38.20 on Thursday. Zai Lab has a 1 year low of $13.48 and a 1 year high of $39.61. The stock’s 50 day simple moving average is $29.47 and its two-hundred day ...
63,909 Shares in Zai Lab Limited (NASDAQ:ZLAB) Acquired by Zurcher Kantonalbank Zurich Cantonalbank
Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Zai Lab Limited (NASDAQ:ZLAB – Free Report) during the fourth quarter, HoldingsChannel reports. The firm purchased 63,909 ...
Scotiabank Initiates Coverage on Zai Lab (NASDAQ:ZLAB)
Scotiabank initiated coverage on shares of Zai Lab (NASDAQ:ZLAB – Free Report) in a research note issued to investors on ...